Aquestive Therapeutics, Inc. AQST R&D credit carryforward
R&D credit carryforward at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch.
The official record: Aquestive Therapeutics, Inc.’s 10-K, filed March 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s r&d credit carryforward.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s r&d credit carryforward?
- Aquestive Therapeutics, Inc. (AQST) reported r&d credit carryforward of $6.91M in Q4 2025.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s r&d credit carryforward?
- Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s r&d credit carryforward has grown at a 17.1% compound annual growth rate (CAGR), from $5.04M to $6.91M.
- What does r&d credit carryforward mean?
- This represents the value of research and development tax credits that have been earned but not yet utilized to offset tax liabilities. These carryforwards provide a future reduction in income tax payments, effectively acting as a tax asset for the company. It is a key indicator of the company's historical investment in innovation and its potential for future tax savings.